home / stock / anab / anab message board
Subject | By | Source | When |
---|---|---|---|
HighPeaks, The NY Times article was | gfp927z | investorshub | 06/10/2022 4:40:20 PM |
Thanks TP. Yeah this has the potential to | HighPeaks | investorshub | 06/10/2022 3:36:11 PM |
Tremendous find HighPeaks. .You have been early on | tedpeele | investorshub | 06/10/2022 5:30:31 AM |
According to this link ANAB gets 8-25% royalties | HighPeaks | investorshub | 06/08/2022 7:33:46 PM |
$ANAB / #Anaptysbio Spikes After Drug Designation | TFMG | investorshub | 07/09/2020 1:28:42 AM |
RSI @ 16. laughable. Zacks has positive take. https://finance.yahoo.com/news/ana | LoveItInBishop | investorshub | 11/18/2019 4:46:05 AM |
* * $ANAB Video Chart 11-13-19 * * | ClayTrader | investorshub | 11/13/2019 8:58:42 PM |
* * $ANAB Video Chart 11-08-19 * * | ClayTrader | investorshub | 11/08/2019 10:08:21 PM |
LOL! Twitter PnD. Buyer beware. | waterchaser | investorshub | 11/08/2019 9:26:03 PM |
Once the real bounce starts it will be fast.... | 420man | investorshub | 11/08/2019 6:25:07 PM |
$10 to da moon :-) | Crazy Money | investorshub | 11/08/2019 5:56:42 PM |
This will bounce..... 15 AH | 420man | investorshub | 11/08/2019 5:44:12 PM |
trying to bounce back over $11, hoping for more | RJ Trotts | investorshub | 11/08/2019 3:08:17 PM |
Ouch - | TaxiCaT | investorshub | 11/08/2019 2:23:32 PM |
Nothing happen here? | celle | investorshub | 05/25/2019 8:20:04 AM |
This stock is making noise! Bought in Sept | manny371 | investorshub | 12/31/2017 3:08:00 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-11-05 22:32:03 ET In a landscape of growth and challenges, the company witnessed a remarkable rise in collaboration revenue, reflecting a successful expansion strategy. However, operating expenses surged, leading to a significant net loss. Management focused on enhancing intellectual pro...
Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024 Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid arthritis (RA) in February 2025 Phase 1 trial initiated in healthy volunteers for ANB033, our anti...
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior man...